WHAT IF there were a way to give cancer a ‘fever’ to enhance the results of chemotherapy and radiation? There is, says Actium BioSystems…
Browsing: chemotherapy
DARA Biosciences has created some buzz as of late, landing on several ‘watch lists’ after the company’s exclusive licensing of three market-ready products for distribution in the United States. CEO/Chief Medical Officer Dr. David Drutz and COO Chris Clement conducted a two-part interview with OneMedRadio discussing developmental milestones and key catalysts for Q4-2012 and 2013.
China Analyst, a financial information website focused on U.S.-listed Chinese stocks, recently released its list of the top 10 pharmaceutical stocks with the highest upside.
The San Diego-based company seeks to improve upon existing cancer therapeutics with its reformulations of the chemotherapy drugs Navelbine and Taxotere.
NuVue Therapeutics is commercializing a site-specific regimen of cancer therapy for soft tissue tumors.
Peregrine Pharmaceuticals reported positive Phase II data in a clinical trial of bavituximab in patients with a deadly form of lung cancer.
A method of delivering chemotherapy drugs into a deadly type of brain tumor extended the lives of patients in early clinical trials.
Clarient is launching a new breast cancer test that helps physicians assess the probability of a patient’s cancer returning.